International Journal of Physical Medicine & Rehabilitation
Open Access

Abstract

Prognosis of Heart Failure and Sympathetic Nerve Activity

Shinya Minatoguchi*

The prognosis of heart failure is poor and plasma noradrenaline level is a good predictor of the survival rate of heart failure patients. Sympathetic nerve activity is augmented in patients with heart failure as evidenced by a higher noradrenaline release rate from the sympathetic nerve endings. Drugs for heart failure such as β-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid antagonists, ivabradine, Angiotensin Receptor-Neprilysin Inhibitor (ARNI), and Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors have clinical evidences for improving prognosis of heart failure in large randomized-controlled clinical trials. Interestingly, the same characteristics in common of these drugs is to reduce sympathetic nerve activity. In addition, cardiac rehabilitation which causes a better prognosis of heart failure reduces the sympathetic nerve activity. In conclusion, to optimize excessively augmented sympathetic nerve activity may be related to an improvement of prognosis of heart failure.

Published Date: 2022-03-23; Received Date: 2022-02-23